Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios menarini sa - dexketoprofentrometamol - filmdragerad tablett - 12,5 mg - propylenglykol hjälpämne; dexketoprofentrometamol 18,45 mg aktiv substans - dexketoprofen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios menarini sa - dexketoprofentrometamol - filmdragerad tablett - 25 mg - dexketoprofentrometamol 36,9 mg aktiv substans; propylenglykol hjälpämne - dexketoprofen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios menarini sa - dexketoprofentrometamol - injektions-/infusionsvätska, lösning - 50 mg/2 ml - dexketoprofentrometamol 36,9 mg aktiv substans; etanol, vattenfri hjälpämne - dexketoprofen

Europeiska unionen - svenska - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - gemenskapsförvärvade infektioner - antibakteriella medel för systemiskt bruk, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 och 5. hänsyn bör tas till officiella riktlinjer för lämplig användning av antibakteriella medel.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios menarini sa - dexketoprofentrometamol - granulat till oral lösning - 12,5 mg - sackaros hjälpämne; dexketoprofentrometamol 18,45 mg aktiv substans - dexketoprofen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios menarini sa - dexketoprofentrometamol - granulat till oral lösning - 25 mg - dexketoprofentrometamol 36,9 mg aktiv substans; sackaros hjälpämne - dexketoprofen

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

laboratorios menarini sa - dexketoprofentrometamol - oral lösning i dospåse - 25 mg - dexketoprofentrometamol 36,9 mg aktiv substans; metylparahydroxibensoat hjälpämne; sackaros hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastiska medel - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Europeiska unionen - svenska - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - multipelt myelom - antineoplastiska medel - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Europeiska unionen - svenska - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - bröst-neoplasmer - endokrin terapi - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.